TWI293249B - A medical composition containing aspirin - Google Patents

A medical composition containing aspirin Download PDF

Info

Publication number: TWI293249B
Authority: TW; Taiwan
Prior art keywords: aspirin; pharmaceutical composition; tetrahydrothiophene; embolism; fluorobenzyl
Prior art date: 2000-12-25

Application number

TW090132160A

Other languages

English (en)

Chinese (zh)

Inventor

Fumitoshi Asai

Atsuhiro Sugidachi

Taketoshi Ogawa

Teruhiko Inoue

Original Assignee

Sankyo Co

Ube Industries

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-25

Filing date

2001-12-25

Publication date

2008-02-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18858878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI293249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-25 Application filed by Sankyo Co, Ube Industries filed Critical Sankyo Co

2008-02-11 Application granted granted Critical

2008-02-11 Publication of TWI293249B publication Critical patent/TWI293249B/zh

Links

BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 23
229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 23
239000000203 mixture Substances 0.000 title description 8
150000003839 salts Chemical class 0.000 claims abstract description 23
208000007536 Thrombosis Diseases 0.000 claims abstract description 22
201000010099 disease Diseases 0.000 claims abstract description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
208000005189 Embolism Diseases 0.000 claims abstract description 17
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 36
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 6
239000004615 ingredient Substances 0.000 claims description 2
150000002688 maleic acid derivatives Chemical class 0.000 claims 1
230000000144 pharmacologic effect Effects 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract description 8
208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 5
230000002401 inhibitory effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 description 16
-1 2-acetoxycyclopropanecarbonyl-2-chloropyridyl Chemical group 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 12
238000011282 treatment Methods 0.000 description 12
150000001875 compounds Chemical class 0.000 description 9
238000000034 method Methods 0.000 description 9
230000000694 effects Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 6
230000002265 prevention Effects 0.000 description 5
229920002472 Starch Polymers 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
235000019426 modified starch Nutrition 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002689 soil Substances 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
206010003402 Arthropod sting Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
244000147568 Laurus nobilis Species 0.000 description 1
235000017858 Laurus nobilis Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241001229889 Metis Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000241413 Propolis Species 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
235000005212 Terminalia tomentosa Nutrition 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001294 alanine derivatives Chemical class 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000005227 alkyl sulfonate group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
150000001509 aspartic acid derivatives Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002306 glutamic acid derivatives Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical group 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000012433 hydrogen halide Substances 0.000 description 1
229910000039 hydrogen halide Inorganic materials 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920002529 medical grade silicone Polymers 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
150000007965 phenolic acids Chemical class 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940069949 propolis Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
238000002271 resection Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
239000004576 sand Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

TW090132160A 2000-12-25 2001-12-25 A medical composition containing aspirin TWI293249B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2000392983		2000-12-25

Publications (1)

Publication Number	Publication Date
TWI293249B true TWI293249B (en)	2008-02-11

Family

ID=18858878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW090132160A TWI293249B (en)	2000-12-25	2001-12-25	A medical composition containing aspirin

Country Status (25)

Country	Link
US (3)	US20040024013A1 (es)
EP (1)	EP1350511B1 (es)
KR (1)	KR100692934B1 (es)
CN (1)	CN100341506C (es)
AT (1)	ATE407675T1 (es)
AU (1)	AU2002217464B2 (es)
BR (1)	BR0116531A (es)
CA (1)	CA2432644C (es)
CY (1)	CY1108626T1 (es)
CZ (1)	CZ297570B6 (es)
DE (1)	DE60135780D1 (es)
DK (1)	DK1350511T3 (es)
ES (1)	ES2311498T3 (es)
HU (1)	HUP0400644A3 (es)
IL (2)	IL156456A0 (es)
MX (1)	MXPA03005770A (es)
NO (1)	NO20032902L (es)
NZ (1)	NZ526540A (es)
PL (1)	PL206138B1 (es)
PT (1)	PT1350511E (es)
RU (1)	RU2262933C2 (es)
SK (1)	SK287972B6 (es)
TW (1)	TWI293249B (es)
WO (1)	WO2002051412A1 (es)
ZA (1)	ZA200304878B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2308633T3 (es) *	2000-07-06	2008-12-01	Daiichi Sankyo Company, Limited	Sal de adicion de maleato de derivados de la hidropiridina.
IL156456A0 (en)	2000-12-25	2004-01-04	Sankyo Co	Pharmaceutical compositions containing aspirin
JP2006525328A (ja) *	2003-05-05	2006-11-09	イーライリリーアンドカンパニー	心疾患の治療方法
CN100488163C (zh) *	2005-01-19	2009-05-13	华为技术有限公司	组播业务处理方法和系统
CN101198329A (zh) *	2005-06-17	2008-06-11	伊莱利利公司	普拉格雷给药方案
DE102005029612A1 (de) *	2005-06-23	2007-01-04	Hochschule Bremen	Vorrichtung zum Erzeugen eines Panoramabildes
EP1940399A2 (en) *	2005-08-19	2008-07-09	Eli Lilly & Company	Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
DK2032521T3 (da) *	2006-06-27	2010-01-25	Sandoz Ag	Ny fremgangsmåde til saltfremstilling
TWI405591B (zh) *	2006-12-07	2013-08-21	Daiichi Sankyo Co Ltd	固形製劑之製造方法
CN101600431B (zh) *	2006-12-07	2011-09-07	第一三共株式会社	具有改进贮存稳定性的药物组合物
KR101442862B1 (ko) *	2006-12-07	2014-09-22	다이이찌 산쿄 가부시키가이샤	만니톨 또는 유당을 함유하는 고형 제제
CA2823981C (en) *	2006-12-07	2016-05-17	Daiichi Sankyo Company, Limited	Film-coated preparation having improved stability
EP2100610A4 (en) *	2006-12-07	2009-12-02	Daiichi Sankyo Co Ltd	PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
DK2123656T3 (da) *	2007-03-02	2014-09-08	Daiichi Sankyo Co Ltd	Fremgangsmåde til fremstilling af prasugrelhydrochlorid med høg renhed
CN101686681B (zh)	2007-04-27	2015-04-01	锡德克斯药物公司	包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
CN101177430A (zh) *	2007-12-11	2008-05-14	鲁南制药集团股份有限公司	氢化吡啶衍生物及其盐的制备方法
US20090281136A1 (en) *	2008-05-08	2009-11-12	Sandeep Mhetre	Prasugrel pharmaceutical formulations
JP2011529859A (ja)	2008-08-02	2011-12-15	ルナンファーマシューティカルグループコーポレーション	プラスグレル重硫酸塩及びその薬物組成物並びにその応用
ES2588759T3 (es)	2009-05-13	2016-11-04	Cydex Pharmaceuticals, Inc.	Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
CN102228691A (zh) *	2011-06-29	2011-11-02	北京阜康仁生物制药科技有限公司	阿司匹林和一种抗血小板药物的药物组合物
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757395B2 (en) *	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
CN105473133A (zh)	2013-04-30	2016-04-06	欧缇托匹克公司	干粉制剂及使用方法
CA2977083A1 (en)	2014-02-20	2015-08-27	Kambiz Yadidi	Dry powder formulations for inhalation
WO2016122421A1 (en)	2015-01-29	2016-08-04	Pharmactive Ilaç Sanayi Ve Ticaret A.Ş.	Stable pharmaceutical compositions containing prasugrel base

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2890240A (en) *	1956-03-28	1959-06-09	Monsanto Chemicals	Aspirin crystallisation
US3235583A (en) *	1964-07-22	1966-02-15	Norwich Pharma Co	Preparation of aspirin
US3890240A (en) *	1966-11-28	1975-06-17	Pitney Bowes Inc	Toner compositions and methods for their preparation
FR2215948B1 (es)	1973-02-01	1976-05-14	Centre Etd Ind Pharma
FR2345150A2 (fr)	1975-08-06	1977-10-21	Centre Etd Ind Pharma	Nouveaux derives de la thienopyridine, et leur application
FR2307538A1 (fr) *	1975-04-18	1976-11-12	Centre Etd Ind Pharma	Nouveau medicament anti-agregant plaquettaire
FR2312247A1 (fr)	1975-05-30	1976-12-24	Parcor	Derives de la thieno-pyridine, leur procede de preparation et leurs applications
FR2358150A1 (fr) *	1976-07-13	1978-02-10	Parcor	Nouvelles thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application
FR2376860A1 (fr) *	1977-01-07	1978-08-04	Parcor	Tetrahydro-4,5,6,7 thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application therapeutique
GB1576511A (en) *	1977-03-29	1980-10-08	Parcor	Thieno(2,3 - c) and (3,2 - c) pyridines process for their preparation and therapeutic applications thereof
GB2038625B (en) *	1978-12-29	1983-01-12	Parcor	Therapeutic composition having an antithrombotic and antiblood-platelet-aggregating activity
CA1147658A (en)	1980-01-03	1983-06-07	Edouard Panak	Therapeutic compositions having antithrombotic and anti-blood-platelet- aggregating activity
US4400384A (en) *	1980-10-06	1983-08-23	Sanofi, S.A.	5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine methanesulfonate and other novel salts thereof
US4321266A (en) *	1980-10-06	1982-03-23	Sanofi	5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-C] pyridine
FR2495156A1 (fr) *	1980-11-28	1982-06-04	Sanofi Sa	Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique
FR2528848A1 (fr) *	1982-06-16	1983-12-23	Sanofi Sa	Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
FR2530247B1 (fr) *	1982-07-13	1986-05-16	Sanofi Sa	Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) *	1985-01-31	1987-03-20	Sanofi Sa	Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FR2596392B1 (fr)	1986-03-27	1988-08-05	Sanofi Sa	Derives de l'acide a-(hydroxy-3 oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenylacetique, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2597102B1 (fr)	1986-04-14	1988-08-26	Sanofi Sa	Derives de l'acide a-(hydroxy-7 tetrahydro-4,5,6,7 thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
FR2652579B1 (fr) *	1989-10-02	1992-01-24	Sanofi Sa	Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique.
US5401730A (en) *	1990-07-06	1995-03-28	The Hope Heart Institute	Method for reducing platelet aggregation
ZA926784B (en) *	1991-09-09	1993-03-29	Sankyo Co	Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation.
FI101150B (fi) *	1991-09-09	1998-04-30	Sankyo Co	Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
CA2087743C (en)	1992-02-06	1999-04-27	Akio Odawara	Pharmaceutical composition for inhibiting platelet aggregation
EP0573975A1 (en)	1992-06-08	1993-12-15	Fuji Photo Film Co., Ltd.	2-alkoxycarbonyl-5-o-chlorobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine derivative and process for producing the same
DK0641770T3 (da)	1993-03-17	1998-06-02	Meiji Seika Co	Hidtil ukendte forbindelser med blodpladeaggegationsinhiberende aktivitet
JPH06271582A (ja)	1993-03-18	1994-09-27	Fuji Photo Film Co Ltd	４，５，６，７−テトラヒドロチエノ〔３，２−ｃ〕ピリジン誘導体の製造方法
WO1996011203A1 (en) *	1994-10-07	1996-04-18	Ube Industries, Ltd.	2-silyloxytetrahydrothienopyridine, salt thereof, and process for producing the same
JP3564791B2 (ja)	1995-04-21	2004-09-15	宇部興産株式会社	α−アミノケトン類の製造方法
FR2744918B1 (fr) *	1996-02-19	1998-05-07	Sanofi Sa	Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
ES2246575T3 (es) *	1998-06-17	2006-02-16	Bristol-Myers Squibb Company	Prevencion del infarto cerebral mediante la administracion de una combinacion de un farmaco antiplaquetario bloqueador del receptor adp y un farmaco antihipertensivo.
US6509348B1 (en) *	1998-11-03	2003-01-21	Bristol-Myers Squibb Company	Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
IT1306980B1 (it)	1999-01-13	2001-10-11	Magneti Marelli Spa	Gruppo motore-cambio di velocita', in particolare per motocicli.
CN1108798C (zh) *	1999-01-26	2003-05-21	广东药学院	一种治疗、预防血栓形成及中风的复方制剂及其制备方法
JP2000266780A (ja)	1999-03-18	2000-09-29	Matsushita Electric Ind Co Ltd	プローブカードとそれを用いた検査装置
IT1311924B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
IT1311923B1 (it)	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
FR2792836B3 (fr)	1999-04-30	2001-07-27	Sanofi Sa	Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
ES2308633T3 (es) *	2000-07-06	2008-12-01	Daiichi Sankyo Company, Limited	Sal de adicion de maleato de derivados de la hidropiridina.
JP4001199B2 (ja)	2000-07-06	2007-10-31	第一三共株式会社	ヒドロピリジン誘導体酸付加塩
EP1332131A2 (en) *	2000-11-07	2003-08-06	Bristol-Myers Squibb Company	Acid derivatives useful as serine protease inhibitors
IL156456A0 (en)	2000-12-25	2004-01-04	Sankyo Co	Pharmaceutical compositions containing aspirin
WO2003011824A1 (en) *	2001-07-31	2003-02-13	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
DE10305984A1 (de) *	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
KR20070052780A (ko) *	2004-09-21	2007-05-22	테바 파마슈티컬 인더스트리즈 리미티드	결정질 클로피도그렐 브롬산염 및 이의 제조 방법
US20110003847A1 (en) *	2008-02-06	2011-01-06	Helm Ag	Prasugrel Salts with Improved Properties
DE202008003557U1 (de)	2008-03-13	2008-06-05	Riela - Getreidetechnik Karl-Heinz Knoop E.K.	Schubwendetrockner mit Feuchte-Messeinrichtung
EP2112155B1 (en)	2008-04-25	2010-09-29	Sandoz AG	Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation
GB2469883A (en)	2009-04-30	2010-11-03	Sandoz Ag	Novel crystalline form of Prasugrel hydrogensulphate
HU3745U (en)	2009-10-01	2010-03-29	Laszlo Borzan	Disk guide device for target disk launcher or bowler equipments

2001
- 2001-12-20 IL IL15645601A patent/IL156456A0/xx active IP Right Grant
- 2001-12-20 RU RU2003118638/15A patent/RU2262933C2/ru active
- 2001-12-20 AU AU2002217464A patent/AU2002217464B2/en not_active Expired
- 2001-12-20 PL PL363183A patent/PL206138B1/pl unknown
- 2001-12-20 DK DK01271850T patent/DK1350511T3/da active
- 2001-12-20 AT AT01271850T patent/ATE407675T1/de active
- 2001-12-20 KR KR1020037008323A patent/KR100692934B1/ko not_active Expired - Lifetime
- 2001-12-20 CA CA2432644A patent/CA2432644C/en not_active Expired - Lifetime
- 2001-12-20 DE DE60135780T patent/DE60135780D1/de not_active Expired - Lifetime
- 2001-12-20 CZ CZ20031660A patent/CZ297570B6/cs not_active IP Right Cessation
- 2001-12-20 MX MXPA03005770A patent/MXPA03005770A/es active IP Right Grant
- 2001-12-20 EP EP01271850A patent/EP1350511B1/en not_active Revoked
- 2001-12-20 HU HU0400644A patent/HUP0400644A3/hu not_active Application Discontinuation
- 2001-12-20 SK SK754-2003A patent/SK287972B6/sk not_active IP Right Cessation
- 2001-12-20 ES ES01271850T patent/ES2311498T3/es not_active Expired - Lifetime
- 2001-12-20 WO PCT/JP2001/011201 patent/WO2002051412A1/ja not_active Ceased
- 2001-12-20 NZ NZ526540A patent/NZ526540A/en not_active IP Right Cessation
- 2001-12-20 PT PT01271850T patent/PT1350511E/pt unknown
- 2001-12-20 CN CNB018227686A patent/CN100341506C/zh not_active Expired - Lifetime
- 2001-12-20 BR BR0116531-3A patent/BR0116531A/pt not_active Application Discontinuation
- 2001-12-25 TW TW090132160A patent/TWI293249B/zh not_active IP Right Cessation
2003
- 2003-06-16 IL IL156456A patent/IL156456A/en unknown
- 2003-06-20 US US10/600,266 patent/US20040024013A1/en active Granted
- 2003-06-23 ZA ZA200304878A patent/ZA200304878B/en unknown
- 2003-06-24 NO NO20032902A patent/NO20032902L/no unknown
2006
- 2006-09-13 US US11/520,168 patent/US8404703B2/en not_active Expired - Fee Related
2008
- 2008-01-03 US US12/006,546 patent/US8569325B2/en not_active Expired - Fee Related
- 2008-12-02 CY CY20081101387T patent/CY1108626T1/el unknown

Also Published As

Publication number	Publication date
NO20032902D0 (no)	2003-06-24
NO20032902L (no)	2003-06-24
US20040024013A1 (en)	2004-02-05
CY1108626T1 (el)	2014-04-09
KR100692934B1 (ko)	2007-03-12
CZ297570B6 (cs)	2007-02-07
HK1056118A1 (en)	2004-02-06
HUP0400644A2 (hu)	2004-06-28
SK7542003A3 (en)	2003-12-02
US20070010499A1 (en)	2007-01-11
DK1350511T3 (da)	2009-01-05
DE60135780D1 (de)	2008-10-23
HUP0400644A3 (en)	2009-06-29
ZA200304878B (en)	2004-08-10
CN1491109A (zh)	2004-04-21
EP1350511A4 (en)	2004-06-23
WO2002051412A1 (en)	2002-07-04
ES2311498T3 (es)	2009-02-16
US20080108589A1 (en)	2008-05-08
NZ526540A (en)	2004-11-26
KR20030065558A (ko)	2003-08-06
CN100341506C (zh)	2007-10-10
ATE407675T1 (de)	2008-09-15
AU2002217464B2 (en)	2004-12-16
CA2432644C (en)	2013-07-23
SK287972B6 (sk)	2012-08-06
PT1350511E (pt)	2008-10-28
US8569325B2 (en)	2013-10-29
MXPA03005770A (es)	2003-09-10
PL363183A1 (en)	2004-11-15
IL156456A0 (en)	2004-01-04
BR0116531A (pt)	2004-02-25
PL206138B1 (pl)	2010-07-30
EP1350511B1 (en)	2008-09-10
US8404703B2 (en)	2013-03-26
CA2432644A1 (en)	2002-07-04
CZ20031660A3 (cs)	2003-12-17
IL156456A (en)	2006-12-10
RU2262933C2 (ru)	2005-10-27
EP1350511A1 (en)	2003-10-08

Publication	Publication Date	Title
TWI293249B (en)	2008-02-11	A medical composition containing aspirin
JP5554699B2 (ja)	2014-07-23	オルメサルタンメドキソミルを含む製剤の溶出性の改善
MX2011006061A (es)	2011-06-24	Composicion farmaceutica solida que comprende amlodipina y losartan con estabilidad mejorada.
JPH04234817A (ja)	1992-08-24	オメプラゾールの直腸投与組成物
PT93654A (pt)	1990-11-20	Processo para a preparacao de composicoes farmaceuticas sinergicas contendo 3-{2-{4-(4-fluoro-benzoil)-1-piperidinil}etil}-2,4-(1h,3h)-quinazolina-diona (ketanserina)
JP4874482B2 (ja)	2012-02-15	アスピリンを含有する医薬組成物
CA3169318A1 (en)	2021-09-02	Pharmaceutical composition for oral administration
KR20220097431A (ko)	2022-07-07	X842의 경구용 제제
KR102222774B1 (ko)	2021-03-04	에독사반을 포함하는 약학적 제제 및 이의 제조방법
JPH02157224A (ja)	1990-06-18	１―ジフェニルメチル―４―［（２―（４―メチルフェニル）―５―メチル―１ｈ―イミダゾール―４―イル）メチル］ピペラジン非経口製剤
JPH01283224A (ja)	1989-11-14	抗高血圧の組み合わせ調合物
JPS6354687B2 (es)	1988-10-28
WO2011126327A2 (en)	2011-10-13	Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
KR102066832B1 (ko)	2020-01-16	텔미사르탄 또는 그의 약제학적으로 허용가능한 염을 포함하는 인습성 및 용출률이 향상된 제제
US3840663A (en)	1974-10-08	5-alkylpipecolic acids as anti-hypertensive agents
WO2006002983A1 (en)	2006-01-12	Combination of organic compounds
JP2000086518A (ja)	2000-03-28	血管攣縮の予防・治療剤
HK1056118B (en)	2009-05-22	Medicinal compositions containing aspirin
JPWO1992001468A1 (ja)	1992-07-02	エンドセリン変換酵素阻害剤または血管攣縮治療剤
TW200406199A (en)	2004-05-01	Preventive and/or therapeutic agent for heart failure
JPH07206678A (ja)	1995-08-08	卵管閉塞治療剤

Legal Events

Date	Code	Title	Description
2022-02-01	MK4A	Expiration of patent term of an invention patent